{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:44:40Z","timestamp":1787499880285,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established up to now. We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib.<\/jats:p>","DOI":"10.1186\/1756-8722-2-19","type":"journal-article","created":{"date-parts":[[2009,5,27]],"date-time":"2009-05-27T02:13:54Z","timestamp":1243390434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report"],"prefix":"10.1186","volume":"2","author":[{"given":"Zhen-gang","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yi","family":"Dun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,28]]},"reference":[{"key":"46_CR1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ajcp\/69.1.86","volume":"69","author":"AR Gaba","year":"1978","unstructured":"Gaba AR, Stein RS, Sweet DL, Variakojis D: Multicentric giant lymph node hyperplasia. American Journal of Clinical Pathology. 1978, 69: 86-90.","journal-title":"American Journal of Clinical Pathology"},{"key":"46_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2006.09.019","volume":"18","author":"TEF Jongsma","year":"2007","unstructured":"Jongsma TEF, Verburg RJ, Geelhoed-Duijvestijn PH: Castleman's disease: A rare lymphoproliferative disorder. European Journal of Internal Medicine. 2007, 18: 87-89. 10.1016\/j.ejim.2006.09.019.","journal-title":"European Journal of Internal Medicine"},{"key":"46_CR3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.ejca.2006.02.015","volume":"42","author":"M Kropff","year":"2006","unstructured":"Kropff M, Bisping G, Wenning D, Berdel W, Kienast J: Protesome inhibition in multiple myeloma. Eur J Cancer. 2006, 42: 1623-1639. 10.1016\/j.ejca.2006.02.015.","journal-title":"Eur J Cancer"},{"key":"46_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF00311511","volume":"26","author":"M Komatsu","year":"1996","unstructured":"Komatsu M, Ehara T, Kuroda T: Cervical Castleman's Disease Associated with Benign M-proteinemia:Report of a Case. Surg Today Jpn J Surg. 1996, 26: 213-216. 10.1007\/BF00311511.","journal-title":"Surg Today Jpn J Surg"},{"key":"46_CR5","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","volume":"74","author":"K Yoshizaki","year":"1989","unstructured":"Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T: Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease. Blood. 1989, 74: 1360-1367.","journal-title":"Blood"},{"key":"46_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7326\/0003-4819-128-8-199804150-00010","volume":"128","author":"J Herrada","year":"1998","unstructured":"Herrada J, Cabanillas F, Rice L, Manning J, Pugh W: The clinical behavior of localized and multicentric Castleman's disease. Annals of Internal Medicine. 1998, 128: 657-662.","journal-title":"Annals of Internal Medicine"},{"key":"46_CR7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.1985.3.9.1202","volume":"3","author":"G Frizzera","year":"1985","unstructured":"Frizzera G, Peterson BA, Bayrd ED, Goldman A: A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. Journal of Clinical Oncology. 1985, 3: 1202-1216.","journal-title":"Journal of Clinical Oncology"},{"key":"46_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1086\/313979","volume":"31","author":"P Kumari","year":"2000","unstructured":"Kumari P, Schechter GP, Saini N, Benator DA: Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. Clinical Infectious Diseases. 2000, 31: 602-604. 10.1086\/313979.","journal-title":"Clinical Infectious Diseases"},{"key":"46_CR9","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1182\/blood-2003-05-1721","volume":"103","author":"C Casper","year":"2004","unstructured":"Casper C, Nichols WG, Huang ML, Corey L, Wald A: Remission of HHV-8 and HIV-associated multicentric Castleman's disease with ganciclovir treatment. Blood. 2004, 103: 1632-1634. 10.1182\/blood-2003-05-1721.","journal-title":"Blood"},{"key":"46_CR10","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1056\/NEJM199403033300904","volume":"330","author":"JT Beck","year":"1994","unstructured":"Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B: Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994, 330: 602-605. 10.1056\/NEJM199403033300904.","journal-title":"N Engl J Med"},{"issue":"8","key":"46_CR11","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"N Nishimoto","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T: Humanized anti-interleukin-6 receptor antibody treatment of Multicentric Castleman's disease. Blood. 2005, 106 (8): 2627-2632. 10.1182\/blood-2004-12-4602.","journal-title":"Blood"},{"key":"46_CR12","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/S0140-6736(99)03957-4","volume":"354","author":"P Rieu","year":"1999","unstructured":"Rieu P, Droz D, Gessain A, Gr\u00fcnfeld JP, Hermine O: Retinoic acid for treatment of multicentric Castleman's disease. The Lancet. 1999, 354: 1262-1263. 10.1016\/S0140-6736(99)03957-4.","journal-title":"The Lancet"},{"key":"46_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ajh.10310","volume":"73","author":"FC Lee","year":"2003","unstructured":"Lee FC, Merchant SH: Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. American Journal of Hematology. 2003, 73: 48-53. 10.1002\/ajh.10310.","journal-title":"American Journal of Hematology"},{"key":"46_CR14","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1182\/blood-2003-03-0951","volume":"102","author":"AG Marcelin","year":"2003","unstructured":"Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N: Rituximab therapy for HIV-associated Castleman's disease. Blood. 2003, 102: 2786-2788. 10.1182\/blood-2003-03-0951.","journal-title":"Blood"},{"issue":"2","key":"46_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0609.2005.00570.x","volume":"76","author":"M Ide","year":"2006","unstructured":"Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T: Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol. 2006, 76 (2): 119-23. 10.1111\/j.1600-0609.2005.00570.x.","journal-title":"Eur J Haematol"},{"issue":"22","key":"46_CR16","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","volume":"25","author":"L G\u00e9rard","year":"2007","unstructured":"G\u00e9rard L, B\u00e9rezn\u00e9 A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 Castlema. B Trial J Clin Oncol. 2007, 25 (22): 3350-3356.","journal-title":"B Trial J Clin Oncol"},{"issue":"12","key":"46_CR17","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1182\/blood-2007-08-106187","volume":"110","author":"T Powles","year":"2007","unstructured":"Powles T, Stebbing J, Montot S: Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman's disease. Blood. 2007, 110 (12): 4132-4133. 10.1182\/blood-2007-08-106187.","journal-title":"Blood"},{"key":"46_CR18","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348: 2609-2617. 10.1056\/NEJMoa030288.","journal-title":"N Engl J Med"},{"key":"46_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005, 23: 630-639. 10.1200\/JCO.2005.11.030.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-2-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:18:55Z","timestamp":1630469935000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-2-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,28]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-2-19","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,28]]},"assertion":[{"value":"10 November 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"19"}}